PubMed:25370155 JSON TXT

Annnotations TAB JSON ListView MergeView

Inflammaging

PubmedHPO

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":215,"end":237},"obj":"HP_0002251"},{"id":"T2","span":{"begin":464,"end":486},"obj":"HP_0002251"}],"text":"Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.\nBACKGROUND: Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung's disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease-associated enterocolitis (HAEC).\nMETHODS: We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4 weeks. In next 3 months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA).\nRESULTS: Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group.\nCONCLUSIONS: Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with ClinicalTrials.gov, NCT number: NCT01934959)."}

wangzhuo19_800

{"project":"wangzhuo19_800","denotations":[{"id":"T1","span":{"begin":0,"end":10},"obj":"CI"},{"id":"T2","span":{"begin":244,"end":254},"obj":"CI"},{"id":"T3","span":{"begin":370,"end":380},"obj":"CI"},{"id":"T4","span":{"begin":408,"end":418},"obj":"CI"},{"id":"T5","span":{"begin":626,"end":636},"obj":"CI"},{"id":"T6","span":{"begin":750,"end":773},"obj":"CI"},{"id":"T7","span":{"begin":791,"end":814},"obj":"CI"},{"id":"T8","span":{"begin":829,"end":839},"obj":"CI"},{"id":"T9","span":{"begin":1160,"end":1183},"obj":"CI"},{"id":"T10","span":{"begin":1277,"end":1287},"obj":"CI"},{"id":"T11","span":{"begin":1470,"end":1493},"obj":"CI"},{"id":"T12","span":{"begin":1508,"end":1518},"obj":"CI"},{"id":"T13","span":{"begin":1642,"end":1652},"obj":"CI"},{"id":"T14","span":{"begin":215,"end":237},"obj":"DP"},{"id":"T15","span":{"begin":238,"end":242},"obj":"DP"},{"id":"T16","span":{"begin":688,"end":699},"obj":"DP"}],"text":"Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.\nBACKGROUND: Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung's disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease-associated enterocolitis (HAEC).\nMETHODS: We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4 weeks. In next 3 months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA).\nRESULTS: Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group.\nCONCLUSIONS: Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with ClinicalTrials.gov, NCT number: NCT01934959)."}

Zierdiyeerkenaili_800_3

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":10},"obj":"CI"},{"id":"T10","span":{"begin":408,"end":418},"obj":"CI"},{"id":"T11","span":{"begin":626,"end":636},"obj":"CI"},{"id":"T12","span":{"begin":1277,"end":1287},"obj":"CI"},{"id":"T13","span":{"begin":1642,"end":1652},"obj":"CI"},{"id":"T14","span":{"begin":688,"end":690},"obj":"DP"},{"id":"T15","span":{"begin":239,"end":241},"obj":"DP"},{"id":"T16","span":{"begin":215,"end":237},"obj":"DP"},{"id":"T2","span":{"begin":244,"end":254},"obj":"CI"},{"id":"T3","span":{"begin":1508,"end":1518},"obj":"CI"},{"id":"T4","span":{"begin":750,"end":759},"obj":"CI"},{"id":"T5","span":{"begin":791,"end":800},"obj":"CI"},{"id":"T6","span":{"begin":1160,"end":1169},"obj":"CI"},{"id":"T7","span":{"begin":1470,"end":1479},"obj":"CI"},{"id":"T8","span":{"begin":829,"end":839},"obj":"CI"},{"id":"T9","span":{"begin":370,"end":380},"obj":"CI"},{"id":"T19","span":{"begin":19,"end":66},"obj":"DP"},{"id":"T20","span":{"begin":464,"end":511},"obj":"DP"},{"id":"T21","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T22","span":{"begin":682,"end":686},"obj":"DP"},{"id":"T23","span":{"begin":909,"end":913},"obj":"DP"},{"id":"T24","span":{"begin":1148,"end":1152},"obj":"DP"},{"id":"T25","span":{"begin":1602,"end":1606},"obj":"DP"},{"id":"T26","span":{"begin":150,"end":152},"obj":"DP"},{"id":"T27","span":{"begin":1230,"end":1232},"obj":"DP"},{"id":"T28","span":{"begin":135,"end":148},"obj":"DP"}],"text":"Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.\nBACKGROUND: Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung's disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease-associated enterocolitis (HAEC).\nMETHODS: We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4 weeks. In next 3 months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA).\nRESULTS: Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group.\nCONCLUSIONS: Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with ClinicalTrials.gov, NCT number: NCT01934959)."}

yaoziqian_800_3

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":19,"end":66},"obj":"DP"},{"id":"T10","span":{"begin":1508,"end":1518},"obj":"CI"},{"id":"T13","span":{"begin":1230,"end":1232},"obj":"DP"},{"id":"T14","span":{"begin":215,"end":237},"obj":"DP"},{"id":"T15","span":{"begin":239,"end":241},"obj":"DP"},{"id":"T16","span":{"begin":688,"end":690},"obj":"DP"},{"id":"T17","span":{"begin":135,"end":148},"obj":"DP"},{"id":"T18","span":{"begin":150,"end":152},"obj":"DP"},{"id":"T19","span":{"begin":829,"end":839},"obj":"CI"},{"id":"T2","span":{"begin":464,"end":511},"obj":"DP"},{"id":"T20","span":{"begin":370,"end":380},"obj":"CI"},{"id":"T21","span":{"begin":408,"end":418},"obj":"CI"},{"id":"T22","span":{"begin":626,"end":636},"obj":"CI"},{"id":"T23","span":{"begin":1277,"end":1287},"obj":"CI"},{"id":"T24","span":{"begin":1642,"end":1652},"obj":"CI"},{"id":"T3","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T4","span":{"begin":682,"end":686},"obj":"DP"},{"id":"T5","span":{"begin":909,"end":913},"obj":"DP"},{"id":"T6","span":{"begin":1148,"end":1152},"obj":"DP"},{"id":"T7","span":{"begin":1602,"end":1606},"obj":"DP"},{"id":"T8","span":{"begin":0,"end":10},"obj":"CI"},{"id":"T9","span":{"begin":244,"end":254},"obj":"CI"},{"id":"T25","span":{"begin":750,"end":759},"obj":"CI"},{"id":"T26","span":{"begin":791,"end":800},"obj":"CI"},{"id":"T27","span":{"begin":1160,"end":1169},"obj":"CI"},{"id":"T28","span":{"begin":1470,"end":1479},"obj":"CI"}],"text":"Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.\nBACKGROUND: Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung's disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung's disease-associated enterocolitis (HAEC).\nMETHODS: We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4 weeks. In next 3 months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA).\nRESULTS: Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group.\nCONCLUSIONS: Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with ClinicalTrials.gov, NCT number: NCT01934959)."}